- Home
- GRND vs ZLAB Comparison
GRND vs ZLAB Comparison
Compare GRND & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRND
- ZLAB
- Stock Information
- Founded
- GRND 2009
- ZLAB 2013
- Country
- GRND United States
- ZLAB China
- Employees
- GRND N/A
- ZLAB N/A
- Industry
- GRND Computer Software: Prepackaged Software
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- GRND Technology
- ZLAB Health Care
- Exchange
- GRND Nasdaq
- ZLAB Nasdaq
- Market Cap
- GRND 4.3B
- ZLAB 3.6B
- IPO Year
- GRND N/A
- ZLAB 2017
- Fundamental
- Price
- GRND $22.53
- ZLAB $36.40
- Analyst Decision
- GRND Strong Buy
- ZLAB Buy
- Analyst Count
- GRND 6
- ZLAB 5
- Target Price
- GRND $23.50
- ZLAB $54.28
- AVG Volume (30 Days)
- GRND 1.6M
- ZLAB 886.6K
- Earning Date
- GRND 08-07-2025
- ZLAB 08-05-2025
- Dividend Yield
- GRND N/A
- ZLAB N/A
- EPS Growth
- GRND N/A
- ZLAB N/A
- EPS
- GRND N/A
- ZLAB N/A
- Revenue
- GRND $363,229,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- GRND $28.97
- ZLAB $44.07
- Revenue Next Year
- GRND $21.80
- ZLAB $49.13
- P/E Ratio
- GRND N/A
- ZLAB N/A
- Revenue Growth
- GRND 30.08
- ZLAB 43.72
- 52 Week Low
- GRND $10.26
- ZLAB $16.01
- 52 Week High
- GRND $25.13
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- GRND 48.49
- ZLAB 52.67
- Support Level
- GRND $21.60
- ZLAB $34.79
- Resistance Level
- GRND $22.99
- ZLAB $36.73
- Average True Range (ATR)
- GRND 0.65
- ZLAB 1.23
- MACD
- GRND -0.07
- ZLAB -0.46
- Stochastic Oscillator
- GRND 44.93
- ZLAB 25.91
About GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.